Table 2.
The effect of selected agents on skeletal-related events (SREs) and pain palliation response based on randomized clinical trials.
| Agent | SRE (% incidence or time to SRE) | Pain palliation response |
|---|---|---|
| Docetaxel versus mitoxantrone [8] | NE | 35% versus 22% (P = 0.01) |
| Abiraterone acetate versus placebo [12, 13] | 25.0 versus 20.3 months (P = 0.0001) | 45% versus 28.8% (P = 0.005) |
| Enzalutamide versus placebo [11, 14] | 16.7 versus 13.3 months (P < 0.0001) | NR |
| Cabazitaxel versus mitoxantrone [74] | NE | 9.2% versus 7.7% (P = 0.63) |
| Zoledronic acid versus placebo [5] | 33.2% versus 44.2% (P = 0.021), 14.9 months versus 10.7 months (P = 0.002) | −0.47% bone pain index (P = 0.024) |
| Denosumab versus zoledronic acid [16] | 20.7 versus 17.1 months (P = 0.0008) | NE |
| Denosumab versus placebo (non-mCRPC) [44] | 29.5 versus 25.3 months (P = 0.0028) | NE |
| Sm-153 versus placebo [18] | NE | 72% pain relief (P < 0.034) |
| Sr-89 [53] | NE | Mean complete pain response 32%, mean partial pain response 44% |
| Ra 223 versus placebo [21] | 15.6 versus 9.8 months (P = 0.00046) | NE |
| Cabozantinib [67] | NE | 64% improvement |
NE: not examined and NR: not reported.